Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early clinical markers of aggressive multiple sclerosis.
Malpas CB, Manouchehrinia A, Sharmin S, Roos I, Horakova D, Havrdova EK, Trojano M, Izquierdo G, Eichau S, Bergamaschi R, Sola P, Ferraro D, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Grand'Maison F, Ozakbas S, Van Pesch V, Granella F, Hupperts R, Pucci E, Boz C, Sidhom Y, Gouider R, Spitaleri D, Soysal A, Petersen T, Verheul F, Karabudak R, Turkoglu R, Ramo-Tello C, Terzi M, Cristiano E, Slee M, McCombe P, Macdonell R, Fragoso Y, Olascoaga J, Altintas A, Olsson T, Butzkueven H, Hillert J, Kalincik T. Malpas CB, et al. Among authors: mccombe p. Brain. 2020 May 1;143(5):1400-1413. doi: 10.1093/brain/awaa081. Brain. 2020. PMID: 32386427 Free article.
Bladder dysfunction in multiple sclerosis.
McCombe PA, Gordon TP, Jackson MW. McCombe PA, et al. Expert Rev Neurother. 2009 Mar;9(3):331-40. doi: 10.1586/14737175.9.3.331. Expert Rev Neurother. 2009. PMID: 19271942 Review.
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists. Broadley SA, et al. Among authors: mccombe pa. J Clin Neurosci. 2014 Nov;21(11):1847-56. doi: 10.1016/j.jocn.2014.01.018. Epub 2014 Jun 28. J Clin Neurosci. 2014. PMID: 24986155 Review.
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists. Broadley SA, et al. Among authors: mccombe pa. J Clin Neurosci. 2014 Nov;21(11):1835-46. doi: 10.1016/j.jocn.2014.01.016. Epub 2014 Jun 30. J Clin Neurosci. 2014. PMID: 24993135 Review.
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists. Broadley SA, et al. Among authors: mccombe pa. J Clin Neurosci. 2014 Nov;21(11):1857-65. doi: 10.1016/j.jocn.2014.01.017. Epub 2014 Jun 30. J Clin Neurosci. 2014. PMID: 24993136 Review.
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H; MSBase Study Group. Kalincik T, et al. Among authors: mccombe p. Ann Neurol. 2015 Mar;77(3):425-35. doi: 10.1002/ana.24339. Epub 2015 Jan 17. Ann Neurol. 2015. PMID: 25546031 Clinical Trial.
292 results